Recce Pharmaceuticals (ASX:RCE) - CEO, James Graham
CEO, James Graham
Source: Finance News Network
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Recce Pharmaceuticals (RCE) has completed its capital raise and successfully raised $27.95 million
  • All up, 21.5 million fully paid ordinary shares will now be issued to institutional, professional and sophisticated investors at $1.30 each
  • Due to the strong support received from investors, Executive Chairman Dr Graham Melrose has agreed to sell more than 1.57 million shares for $2.05 million
  • Recce will use the money to advance its antibiotics, complete phase one human clinical trials, and fund anticipated phase one and two topical studies
  • Shares are expected to be issued on or around September 30
  • Recce is down 3.67 per cent on the market and shares are trading for $1.58 each

Recce Pharmaceuticals (RCE) has completed its capital raise and successfully raised $27.95 million.

The antibiotic maker entered a trading halt on September 21 but did not disclose how much it would be raising.

All up, 21.5 million fully paid ordinary shares will now be issued to institutional, professional and sophisticated investors at $1.30 each.

This price represents a 20.5 per cent discount to the $1.64 closing price of RCE shares on September 18, and a 16 per cent discount to the 20-day volume-weighted average price of $1.55.

Due to the strong support received from investors, Executive Chairman Dr Graham Melrose has agreed to sell 1,576,923 shares for $2.05 million.

Recce will use the money to advance its RECCE 327, RECCE 435 and RECCE 529 antibiotics, complete phase I human clinical trials, and fund anticipated phase I and II topical studies.

“We greatly appreciate the support shown by both our existing investors and new institutional investors. Their financial support comes at a transformative time for Recce as we prepare to advance human clinical trials,” CEO James Graham said.

Shares are expected to be issued on or around September 30.

Recce is down 3.67 per cent on the market and shares are trading for $1.58 each at 1:04 pm AEST.

RCE by the numbers
More From The Market Online
Saccharomyces cerevisiae yeast, 3D illustration.

Tissue Repairs soars nearly 32% on TGA approval for wound healing gel

Biotech company Tissue Repair Ltd (ASX:TRP) has seen its share price rise more than 30% on news it had gained TGA (Therapeutic
The Market Online Video

Little Green Pharma (ASX:LGP) reports revenue increase in Q4 FY24

This interview discusses Little Green Pharma’s (ASX:LGP) record-breaking quarterly results for June 2024, highlighting a 12% increase in revenue and significant cash receipts.
Illustration representing big data technology.

Opyl forms JV with UK and US consortium to bring products to the world

Medical technology and AI company Opyl Ltd is set to form a joint venture with UK…
Ai gen brain scan

EMVision Medical successfully fabs first prototype of First Responder brain scan device – portable enough for a backpack

EMVision Medical Devices (ASX:EMV) has announced its successful fabrication of a portable on-the-spot brain scanning device.